-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Total costs of sales and operating expenses for the period.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2020 to Q2 2024.
- Inhibikase Therapeutics, Inc. Costs and Expenses for the quarter ending June 30, 2024 was $5.05M, a 20.1% decline year-over-year.
- Inhibikase Therapeutics, Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $19.1M, a 4.66% decline year-over-year.
- Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2023 was $20.4M, a 11.5% increase from 2022.
- Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2022 was $18.3M, a 2.16% increase from 2021.
- Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2021 was $17.9M, a 408% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)